Accolade Stock on Pace for All-Time Low as Guidance Disappoints. The Case to Buy the Dip.

Accolade stock was falling sharply after its earnings report disappointed. Analyst Jack Wallace lowered his price target on the tech and health company to $6 from $13, while maintaining a Buy rating on the stock. Wallace added the optimism was fueled by his belief that the stock’s valuation is at a bottom, and management’s lowering of its fiscal-year guidance is a “clearing of the decks move that should allow ACCD to at least meet, if not exceed, guidance for the rest of the year.”